{
    "nctId": "NCT04573231",
    "briefTitle": "Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer",
    "officialTitle": "Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 13,
    "primaryOutcomeMeasure": "PSMA Expression as measured by 18F-DCFPyL SUV",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients diagnosed with metastatic HER2-negative breast cancer AR expression of \u2265 10%\n\nExclusion Criteria:\n\n* Other (non-breast) known active malignancy. Participants with previously treated cancers which are in remission or have no evidence of disease are eligible.\n* Unable to lie flat during or tolerate PET/CT\n* Participants with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety or compliance of the subject to produce reliable data or completing the study\n* Women of childbearing potential must not be pregnant or breast feeding (pregnancy test negative within 7 days prior to PET/CT",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}